Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hepatocellular carcinoma
(
HCC
) is the most common subtype of liver malignancy, and it is characterized by poor prognosis because of cancer stem cell (CSC)-mediated high postsurgical recurrence rates. Thus, targeting CSCs, or
HCC
cells with CSC-like properties, is an effective strategy for
HCC
therapy. Here, using long noncoding RNA (lncRNA) microarray analysis, we identified a novel lncRNA termed lncCAMTA1 that is increased in both liver CSCs and
HCC
. High lncCAMTA1 expression in
HCC
indicates poor clinical outcome. In vitro and in vivo functional experiments showed that overexpression of lncCAMTA1 promotes
HCC
cell proliferation, CSC-like properties, and tumorigenesis. Conversely, depletion of lncCAMTA1 inhibits
HCC
cell proliferation, CSC-like properties, and tumorigenesis. Mechanistically, we demonstrated that lncCAMTA1 physically associates with the
calmodulin binding transcription activator 1
(
CAMTA1
) promoter, induces a repressive chromatin structure, and inhibits
CAMTA1
transcription. Furthermore,
CAMTA1
is required for the effects of lncCAMTA1 on
HCC
cell proliferation and CSC-like properties, and the expression of lncCAMTA1 and
CAMTA1
is significantly negatively correlated in
HCC
tissues. Collectively, our study revealed the important roles and underlying molecular mechanisms of lncCAMTA1 on
HCC
, and suggested that lncCAMTA1 could be an effective prognostic factor and a potential therapeutic target for
HCC
.
...
PMID:Long Noncoding RNA lncCAMTA1 Promotes Proliferation and Cancer Stem Cell-Like Properties of Liver Cancer by Inhibiting CAMTA1. 2766 32